Objective: To study the effect of a new fermented milk product containing GABA (FMG) on the blood pressure (BP) of patients with mild hypertension. Design: A randomized, placebo-controlled, single-blind trial. Setting: The study was carried out at the outpatient clinic of the Cardiovascular Disease Center, Tokyo Metropolitan Police Hospital, Japan. Subjects: The study population comprised 39 mildly hypertensive patients (16 women and 23 men) aged 28 -81 y (mean, 54.2 y). Interventions: The study consisted of a 12-week period of daily intake of FMG or placebo (weeks 1 -12) followed by 2 weeks of no intake (weeks 13 and 14). We measured the peripheral BP and heart rate of seated patients at weeks 0, 2, 4, 8, 12 and 14. Routine blood study and urinalysis were performed before and after the intake. Results: There was a significant decrease of BP within 2 or 4 weeks, and it remained decreased throughout the 12-week intake period. For the FMG recipients, the mean decrease after 12 weeks was 17.4 AE 4.3 mmHg in the systolic BP (SBP) and 7.2 AE 5.7 mmHg in the diastolic BP (DBP). Both of these values differed statistically from baseline levels (P < 0.01), and the SBP of the FMG group differed from the placebo group (P < 0.05). Heart rate, body weight, hematological and blood chemistry variables, and urinalysis results (glucosuria and proteinuria) did not vary both groups throughout the study. Conclusion: FMG may contribute to lowering BP in mildly hypertensive people.
Introduction
Dietary and lifestyle changes are the first level of care recommended for mildly hypertensive people. Measures include reduced intake of sodium chloride and alcohol and increased intake of fruit and vegetables containing high levels of calcium, magnesium and potassium (Guidelines of the Subcommittee of WHO=ISH, 1999) .
g-Aminobutyric acid (GABA) is available from many vegetables and fruit. This amino acid has been reported to reduce blood pressure (BP) in experimental animals (Takahashi et al, 1955) and man (Elliott & Hobbiger, 1959) . The BP-lowering effect of GABA is due in part to its ability to block peripheral ganglia (Stanton, 1963) . In spontaneously hypertensive rats, GABA has an antihypertensive effect, possibly through the inhibition of noradrenaline release from sympathetic nerve endings (Hayakawa et al, 2002) .
We recently have produced a new type of fermented milk containing GABA by using two kinds of starters -Lactobacillus casei strain Shirota, and Lactococcus lactis YIT 2027. The Lb. casei strain hydrolyzes milk protein into glutamic acid, and the Lc. lactis converts glutamic acid into GABA (unpublished observation). We have confirmed that this new fermented milk product has a BP-lowering effect in spontaneously hypertensive rats (Hayakawa et al, 2002, unpublished observation) . In the present study, we assessed the effect of oral intake of this new GABA-containing fermented milk on BP among people with mild hypertension.
Subjects and methods

Subjects
The study population comprised 39 patients with mild hypertension (WHO=ISH grade 1 -2=level I -II) enrolled in our outpatient clinic. Baseline SBP ranged from 140 to 159 mmHg and DBP ranged from 90 to 99 mmHg among these patients when seated. Criteria of patient selection were: age at least 20 y; no history of antihypertensive medication; no other illnesses; and nonpregnant. The patients were advised to maintain a moderate lifestyle regarding their eating habits, exercise, sleep, daily work, smoking, alcohol intake, etc during this study. We interviewed participants before and throughout the study to ensure their compliance with these lifestyle requirements. Subjects provided written informed consent to participation. This study was approved by the Ethics Committee and New Trial Drug Committee of our hospital.
Study protocol
This study was carried out using a placebo-controlled, singleblind design and consisted of a 12-week daily-intake phase (weeks 1 -12) followed by 2 weeks without intake (weeks 13 and 14). The subjects were randomly assigned into two subgroups. One group of patients (n ¼ 20) took 100 ml of FMG daily at breakfast time for 12 weeks. Instead of FMG, the other group (n ¼ 19) took an acidified milk drink without GABA, as a placebo. We measured the BP and heart rate (HR) of seated patients at weeks 0, 2, 4, 8, 12 and 14. At each of these hospital visits, we assessed patients for any side effects and we confirmed appropriate dosage by verifying the checksheets, which subjects had to mark daily when they ingested the product. Once from each patient before and after the 12-week intake period, we obtained fasting blood samples and voided urine samples in the morning for routine blood studies and urinalysis (glucosuria and proteinuria).
Test products
The fermented milk containing GABA (FMG) and placebo were prepared by Yakult Honsha Co. Ltd (Tokyo, Japan). The FMG was produced from skim milk that had been fermented by using 2 starters -Lb. casei strain Shirota and Lc. lactis YIT 2027 -with added sweeteners. The placebo was prepared by adding L-lactic acid and sweeteners to skimmed milk to mimic the taste of FMG. Both drinks had a similar nutritional composition. The concentration of GABA was 10 -12 mg=100 ml in FMG and undetectable in the placebo.
Measurements
BP and HR were measured between 09:00 and 11:30 at our outpatient clinic. The measurements of BP were done by using an ACOMA sphygmomanometer (ACOMA Medical Industry Co., Tokyo, Japan) on seated patients after they had rested for 10 min. Mean BP (MBP) was calculated by using the conventional formula, diastolic BP (DBP) þ 1=3 (systolic BP (SBP) 7 DBP), and we categorized the BP-lowering effect according to four grades (decreased, a drop of ! 13 mmHg; mildly decreased, a drop of 7 -12 mmHg; no change, a change of AE6 mmHg; increased, a rise of ! 7 mmHg; Ministry of Health, Labor and Welfare in Japan, 1989) in MBP. The blood studies and urinalyses were performed at the central laboratory of our hospital. The GABA concentration in the drink samples was measured by using high-performance liquid chromatography (Pawlowska et al, 1993) according to the AccQ-Tag method (Nihon Waters K.K., Tokyo, Japan) at the Yakult Central Institute for Microbiological Research.
Statistical analysis
Data are presented as the mean AE the standard error of the mean (s.e.m.). Dunnett's test was used to analyze changes between the post-intake and baseline levels. Differences between control and post-intake values were analyzed by using paired t-tests. Student's t-test was used to compare the FMG and placebo groups. All statistical analyses were twotailed, and statistical significance was established at P < 0.05. All of these analyses were performed by using SAS System version 6.12 (SAS Institute Inc., Cary, NC, USA).
Results
Subject characteristics and side effects
Of the 39 patients that took part in this study, four subsequently were excluded: two patients in the FMG group did not visit the clinic when required and thus did not complete the study (because of personal reasons that were unrelated to their health conditions or to side effects); one patient in the placebo group took an antihypertensive drug during the study period; and another patient in the placebo group developed a mild stomach ulcer that was clearly not due to the intake of acidified milk. None of the patients in either group developed any side effects. Table 1 includes the baseline demographics of the 35 subjects enrolled in our study. The results of all routine blood studies and urinalyses were within normal ranges. The two groups were similar regarding sex, age, body weight, BP, HR, hematology, urinalysis, and lifestyle (ie eating, exercise, sleep, daily work, smoking and alcohol intake habits). In addition, their lifestyles did not change before, during or after FMG or placebo intake.
Blood pressure and heart rate Figure 1 presents time courses of the SBP, DBP and MBP values after daily intake of FMG or the placebo. Whereas SBP Blood-pressure-lowering effect of a novel fermented milk K Inoue et al and MBP decreased significantly from baseline values during the intake period in the FMG group, these levels did not similarly change in the placebo group. DBP decreased significantly after 2 weeks in the FMG group and after 8 weeks in the placebo group. Figure 2 shows the changes in the SBP, DBP and MBP compared with baseline levels. The decreases in the SBP at 4, 8 and 12 weeks after FMG intake were 13.4 AE 4.1 mmHg (mean AE s.e.m.; P < 0.01), 11.1 AE 3.7 mmHg (P < 0.05), and 17.4 AE 4.3 mmHg (P < 0.01), respectively. These changes differed significantly (P < 0.05) from those of the placebo at Blood-pressure-lowering effect of a novel fermented milk K Inoue et al 4 and 12 weeks but not at 8 weeks. Two weeks after FMG ingestion stopped (week 14), SBP increased but remained lower than the baseline level (P < 0.05). In contrast, no significant changes in SBP occurred in the placebo group. The DBP decreased significantly different from baseline by 4.5 AE 1.9 mmHg (P < 0.05) in the FMG group after 2 weeks of consuming the product. In the placebo group, the decrease was 6.1 AE 1.6 mmHg after 8 weeks (P < 0.01). The reduction in the MBP of the FMG group differed significantly from baseline after 4, 8 and 12 weeks by 10.3 AE 2.3 mmHg (P < 0.01), 9.3 AE 1.7 mmHg (P < 0.01) and 10.6 AE 2.0 mmHg (P < 0.01), respectively. In contrast, this parameter did not change significantly in the placebo group throughout the intake period.
We classified the level of change in MBP into four grades (decreased, mildly decreased, no change and increased) as shown in Figure 3 . After 2 weeks of intake, the percentage of subjects whose MBP decreased by at least 13 mmHg (the grade 'decreased') was 17%, and this proportion increased with time during the intake period. After 12 weeks of intake, the MBP had decreased (the grades 'mildly decreased' and 'decreased') in 83% of the subjects. However, 2 weeks after ceasing intake of FMG (ie the 14-week time point), the percentage of patients in the decreased category was reduced. Where appropriate, data are presented as the mean AE the standard error of the mean. *P < 0.05 (paired t-test) vs baseline. **P < 0.01 (paired t-test) vs baseline. Figure 3 The level of FMG-induced change in the MBP at various times during the intake period was classified into four grades (n ¼ 14 -18): decreased (black bars) -the MBP fell by at least 13 mmHg during the intake period; mildly decreased (hatched bars) -the decrease was 7 -12 mmHg; no change (dotted bars) -the increase or decrease in the MBP was 6 mmHg or less; and increased (open bars) the MBP increased by at least 7 mmHg. The numbers in the bars represent the percentages of subjects in the groups.
Blood-pressure-lowering effect of a novel fermented milk K Inoue et al HR did not change significantly in either group at any point. The baseline HR was 68.2 AE 1.4 beats=min in the FMG group and 73.6 AE 1.9 beats=min in the placebo group. After 12 weeks of FMG or placebo intake, HRs were 69.0 AE 2.5 beats=min and 70.7 AE 1.2 beats=min, respectively. Table 2 presents the results of hematology, blood chemistry studies, and urinalyses before and after intake of FMG. The hematocrit of groups decreased significantly, and red blood cell counts and hemoglobin concentration decreased significantly in the placebo group. However, despite the statistically significant changes, all of these values remained within normal ranges. No other hematologic index showed significant change from the baseline, and there were no significant differences between two groups with respect to these other indices. Blood chemistry values did not change significantly after intake of either product, and there were no significant differences between the two groups. Glucosuria and proteinuria were not detected before or after 12 weeks of intake of FMG or placebo.
Blood study and urinalysis
Discussion
The purpose of this study was to test the safety of FMG and its ability to reduce BP. In this study, 100 ml of FMG taken daily for 12 weeks lowered SBP and DBP in mildly hypertensive patients without affecting HR; the placebo had no such effects. These results highlight the potential of FMG for lowering BP in patients with mild hypertension.
Several constituents in milk have been reported to lower BP. A negative association between calcium intake from dairy products and BP has been demonstrated (Jorde & Bønaa, 2000) , although the lowering effect of this nutrient is small (Miller et al, 2000) . It also has been reported that the ingestion of magnesium decreases BP in hypertensive subjects (Kawano et al, 1998) . SBP was reduced in healthy subjects by the intake of whey-protein-rich fermented milk (Kawase et al, 2000) . Our results clarified that FMG intake lowered the SBP significantly, whereas placebo intake did not. Our subjects did not change their diet or lifestyle before or during the trial. We thus concluded that the difference between the two groups regarding the BP-lowering effect of FMG is not due to any of the constituents naturally in milk.
Various lactic acid bacteria produce specific peptides that possess an inhibitory activity on the angiotensin-converting enzyme (ACE) in vitro and demonstrate a hypotensive effect in the hypertensive rat model (Nakamura et al, 1995; Yamamoto et al, 1999) . We therefore examined the inhibitory activity of FMG on ACE. The results showed FMG had no inhibitory activity at all (data not shown). We therefore concluded that the starters we used did not produce any hypotensive peptides from milk protein and that the BPlowering effect of FMG on mildly elevated BP was because of the presence of GABA.
It is well known that GABA is one of the most important inhibitory neurotransmitters in the central nervous system of mammals (Nicol et al, 1990) . Many studies have confirmed that GABA is present in several peripheral tissues and acts as a neurotransmitter or to modulate endocrine and exocrine functions (Tanaka, 1985; Erdö & Wolff, 1990) . It was first reported in 1955 that intravenous administration of GABA had a hypotensive effect in experimental animals (Takahashi et al, 1955) . Reports addressing the hypotensive effect of intravenous GABA in animals have increased gradually since the 1980s. Dose-dependent effects were observed in the range of 1 -1000 mg=kg (Billingsley & Suria, 1982) , and the degree of the hypotensive effect was positively related to the magnitude of the resting BP (Giuliani et al, 1986) .
In comparison with the numerous animal studies, human clinical studies addressing GABA usage have been rare until recently. In 1959, Elliott & Hobbiges intravenously injected healthy male volunteers with 50 -100 mg of GABA and observed hypotension of more than 25 mmHg. Oral administration of GABA of 3 g daily to hypertensive patients was performed in Japan (Research Group of g-Aminobutyric Acid in Tokyo, 1960) . In this trial, the BP of 51 of the 67 subjects (76%) fell immediately or gradually by an average of 37 mmHg (SBP) and 13 mmHg (DBP), whereas normotensive subjects did not exhibit a change in their normal BP. Our present results show that consumption of only 10 mg of GABA daily for 12 weeks was effective for people with mild hypertension.
Although the mechanism underlying the hypotensive action of systemically administered GABA has not been fully elucidated to date, several hypotheses have been postulated. One of them is as follows. Because GABA hardly passes the blood -brain barrier (Van Gelder & Elliott, 1958; Kuriyama & Sze, 1971) , this molecule acts not in the central nervous system but in the peripheral. In our previous study, GABA inhibited not only the perivascular nerve stimulationinduced increase in perfusion pressure in the mesenteric arterial bed from spontaneously hypertensive rats but also the accompanying noradrenaline release through the molecule's action on presynaptic GABA B receptors. Because GABA did not produce any vasodilatory response, the GABAinduced antihypertensive effect may be due to its inhibition of noradrenaline release from sympathetic nerve fibers (Hayakawa et al, 2002) .
Recently, a few studies have reported that various dietary materials or products containing GABA decreased BP in hypertensive patients in Japan. Gabaron tea (Oomori et al, 1987) , extracts of beni-koji (Tsuji et al, 1992) , and a particular germ of rice (Onoda et al, 1998) were included among these supplements. However, these dietary materials or products contain many ingredients besides GABA, and their effects were not ruled out, although it was presumed that the hypotensive effect was due to the presence of GABA.
Our present study is the first report of a placebocontrolled trial in which the difference between the products ingested by the experimental and control groups is the presence or absence of GABA. Further, FMG is a safe dietary product, because we observed no side-effects or noteworthy changes in hematologic and biochemical indices during or after the 12-week intake period. Therefore, daily intake of fermented milk containing GABA may be helpful in controlling BP levels in mildly hypertensive patients. GABA is present in many vegetables and fruit. The low incidence of hypertension among vegetarians, therefore, may be partly attributable to their ingestion of GABA via these foods; however, further studies are required to confirm this theory.
